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83 Inhaled but not intravenous milrinone prevents pulmonary endothelial
dysfunction after cardiopulmonary bypass
Y. Lamarche, MD, O. Malo, MSc, E. Thorin, PhD, A. Denault, MD, M. Carrier, MD, MSc,
J. Roy, CPP, and L. P. Perrault, MD, PhD, Montreal, Quebec, Canada
CPB triggers a systemic inflammatory response that can contribute to pulmonary hypertension.
Administration of inhaled milrinone before CPB in a swine model has a favorable effect on the
pulmonary endothelial function, hemodynamics, and oxygenation when compared with
intravenous milrinone because of the increased cAMP content of the pulmonary arteries.
93 The effects of steroids on the occurrence of postoperative atrial fibrillation
after coronary artery bypass grafting surgery: A prospective randomized
trial
Kriengchai Prasongsukarn, MD, MSc, James G. Abel, MD, MSc, W. R. Eric Jamieson, MD,
Anson Cheung, MD, James A. Russell, MD, Keith R. Walley, MD, and
Samuel V. Lichtenstein, MD, PhD, Vancouver, British Columbia, Canada
A double-blind randomized controlled study was conducted to examine the effect of steroids on
new-onset postoperative AF in patients undergoing first-time CABG. The steroid group
demonstrated a 50% reduction in AF but had an increase in minor postoperative complications.
99 Reloading the heart: A new animal model of left ventricular assist device
removal
Tomohiro Mizuno, MD, Richard D. Weisel, MD, and Ren-Ke Li, MD, PhD, Toronto, Ontario,
Canada
A new heterotopic heart transplantation model was established to simulate unloading the heart
during support with an LVAD and cardiac reloading after removal of the device. The heart size
decreased in the unloaded state, and the heart dilated after reloading.
107 Recombinant human antithrombin III restores heparin responsiveness and
decreases activation of coagulation in heparin-resistant patients during
cardiopulmonary bypass
M. S. Avidan, MD, J. H. Levy, MD, H. van Aken, MD, R. O. Feneck, MD, R. D. Latimer, MD,
E. Ott, MD, E. Martin, MD, D. E. Birnbaum, MD, L. J. Bonfiglio, BSN, CRNA,
D. K. Kajdasz, PhD, and G. J. Despotis, MD, St Louis, Mo; Atlanta, Ga; Munich, Heidelberg,
Regensberg, and Mu¨nster, Germany; London, United Kingdom; Framingham, Mass; and
Indianapolis, Ind
This study evaluated the efficacy of recombinant human antithrombin III (rhATIII) for the
restoration of heparin responsiveness in heparin-resistant patients undergoing cardiac surgery.
There were no serious adverse events, including bleeding, associated with rhATIII. Fresh frozen
plasma, when transfused, did not restore heparin responsiveness. RhATIII was effective in
restoring heparin responsiveness.
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